These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 28146613)

  • 1. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH
    J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
    J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry PP; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
    J Affect Disord; 2018 Dec; 241():425-432. PubMed ID: 30145513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
    Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
    CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
    Keck PE; Calabrese JR; McIntyre RS; McQuade RD; Carson WH; Eudicone JM; Carlson BX; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2007 Oct; 68(10):1480-91. PubMed ID: 17960961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder.
    Szegedi A; Durgam S; Mackle M; Yu SY; Wu X; Mathews M; Landbloom RP
    Am J Psychiatry; 2018 Jan; 175(1):71-79. PubMed ID: 28946761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
    Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
    Findling RL; Nyilas M; Forbes RA; McQuade RD; Jin N; Iwamoto T; Ivanova S; Carson WH; Chang K
    J Clin Psychiatry; 2009 Oct; 70(10):1441-51. PubMed ID: 19906348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
    McIntyre RS; Such P; Yildirim M; Madera-McDonough J; Zhang Z; Larsen F; Harlin M
    Curr Med Res Opin; 2023 Jul; 39(7):1021-1030. PubMed ID: 37272079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
    Keck PE; Calabrese JR; McQuade RD; Carson WH; Carlson BX; Rollin LM; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2006 Apr; 67(4):626-37. PubMed ID: 16669728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
    Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
    Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole IM depot as an option for the treatment of bipolar disorder.
    Kotzalidis GD; Rapinesi C; Chetoni C; De Filippis S
    Expert Opin Pharmacother; 2021 Aug; 22(11):1407-1416. PubMed ID: 33847183
    [No Abstract]   [Full Text] [Related]  

  • 17. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial.
    Woo YS; Bahk WM; Chung MY; Kim DH; Yoon BH; Lee JH; Ahn YM; Chung SK; Kim JG; Lee KH; Paik KC
    Hum Psychopharmacol; 2011 Dec; 26(8):543-53. PubMed ID: 22134973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
    Ishigooka J; Nakamura J; Fujii Y; Iwata N; Kishimoto T; Iyo M; Uchimura N; Nishimura R; Shimizu N;
    Schizophr Res; 2015 Feb; 161(2-3):421-8. PubMed ID: 25556976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).
    Weisler RH; Nolen WA; Neijber A; Hellqvist A; Paulsson B;
    J Clin Psychiatry; 2011 Nov; 72(11):1452-64. PubMed ID: 22054050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.